title: Haemodynamic, endocrine and renal actions of adrenomedullin 5 in an ovine model of heart failure.
abstract: AM5 (adrenomedullin 5), a newly described member of the CGRP (calcitonin gene-related peptide) family, is reported to play a role in normal cardiovascular physiology. The effects of AM5 in HF (heart failure), however, have not been investigated. In the present study, we intravenously infused two incremental doses of AM5 (10 and 100 ng/min per kg of body weight each for 90 min) into eight sheep with pacing-induced HF. Compared with time-matched vehicle control infusions, AM5 produced progressive and dose-dependent increases in left ventricular dP/dt(max) [LD (low dose), +56 mmHg/s and HD (high dose), +152 mmHg/s] and cardiac output (+0.83 l/min and +1.81 l/min), together with decrements in calculated total peripheral resistance (-9.4 mmHg/min per litre and -14.7 mmHg/min per litre), mean arterial pressure (-2.8 mmHg and -8.4 mmHg) and LAP (left atrial pressure; -2.6 mmHg and -5.6 mmHg) (all P<0.001). HD AM5 significantly raised PRA (plasma renin activity) (3.5-fold increment, P<0.001), whereas plasma aldosterone levels were unchanged over the intra-infusion period and actually fell in the post-infusion period (70% decrement, P<0.01), resulting in a marked decrease in the aldosterone/PRA ratio (P<0.01). Despite falls in LAP, plasma atrial natriuretic peptide and B-type natriuretic peptide concentrations were maintained relative to controls. AM5 infusion also induced significant increases in urine volume (HD 2-fold increment, P<0.05) and urine sodium (2.7-fold increment, P<0.01), potassium (1.7-fold increment, P<0.05) and creatinine (1.4-fold increment, P<0.05) excretion and creatinine clearance (60% increment, P<0.05). In conclusion, AM5 has significant haemodynamic, endocrine and renal actions in experimental HF likely to be protective and compensatory in this setting. These results suggest that AM5 may have potential as a therapeutic agent in human HF.
authors.affiliation: Christchurch Cardioendocrine Research Group, University of Otago, Christchurch, New Zealand. miriam.rademaker@otago.ac.nz
authors.forename: Miriam T
authors.initials: MT
authors.lastname: Rademaker
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Charles
authors.forename: M Gary
authors.initials: MG
authors.lastname: Nicholls
authors.forename: A Mark
authors.initials: AM
authors.lastname: Richards
mesh_terms: D053607:Adrenomedullin / Q000008:administration & dosage / Q000145:classification / Q000494:pharmacology* / Q000502:physiology; D000450:Aldosterone / Q000097:blood; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000097:blood; D000242:Cyclic AMP / Q000097:blood; D004195:Disease Models, Animal; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D020097:Natriuretic Peptide, Brain / Q000097:blood; D012083:Renin / Q000097:blood; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D015290:Second Messenger Systems / Q000187:drug effects; D034561:Sheep, Domestic
chemical_list: D020097:Natriuretic Peptide, Brain; D053607:Adrenomedullin; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D000242:Cyclic AMP; D012083:Renin
references.citation: Hypertension. 1995 Apr;25(4 Pt 2):790-5
references.pmid: 7721434
references.citation: FEBS Lett. 1994 Jan 24;338(1):6-10
references.pmid: 8307158
references.citation: Biochem Biophys Res Commun. 2003 Nov 28;311(4):1072-7
references.pmid: 14623291
references.citation: J Appl Physiol (1985). 2006 Sep;101(3):778-84
references.pmid: 16763098
references.citation: Eur J Pharmacol. 2007 Mar 8;558(1-3):128-32
references.pmid: 17204266
references.citation: Am J Physiol Heart Circ Physiol. 2006 Mar;290(3):H1120-7
references.pmid: 16227344
references.citation: Endocrinology. 2006 Apr;147(4):1871-7
references.pmid: 16410298
references.citation: Br Heart J. 1984 Nov;52(5):524-9
references.pmid: 6093837
references.citation: Am J Physiol. 1996 Feb;270(2 Pt 2):H594-602
references.pmid: 8779835
references.citation: Acta Physiol Scand. 1996 Feb;156(2):151-2
references.pmid: 8868273
references.citation: Int Rev Cytol. 2002;221:1-92
references.pmid: 12455746
references.citation: Br J Pharmacol. 2009 Aug;157(8):1502-13
references.pmid: 19681873
references.citation: Clin Sci (Lond). 2005 Jan;108(1):23-36
references.pmid: 15476436
references.citation: Eur J Pharmacol. 2004 Aug 16;497(1):75-80
references.pmid: 15321737
references.citation: Biochem Biophys Res Commun. 1993 Apr 30;192(2):553-60
references.pmid: 8387282
references.citation: Circulation. 2000 Feb 8;101(5):498-503
references.pmid: 10662746
references.citation: Hypertension. 1997 May;29(5):1148-55
references.pmid: 9149680
references.citation: J Endocrinol. 2002 Apr;173(1):123-9
references.pmid: 11927391
references.citation: Am J Physiol. 1998 Sep;275(3):F410-4
references.pmid: 9729514
references.citation: Eur J Pharmacol. 1999 Oct 1;382(1):1-9
references.pmid: 10556498
references.citation: Circulation. 1993 Jan;87(1):192-8
references.pmid: 8419007
references.citation: Am J Physiol. 1989 Apr;256(4 Pt 2):H1052-9
references.pmid: 2565090
references.citation: Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1536-44
references.pmid: 17526650
references.citation: Am J Physiol Regul Integr Comp Physiol. 2008 Dec;295(6):R2075-83
references.pmid: 18922959
references.citation: J Endocrinol. 2008 May;197(2):391-400
references.pmid: 18434369
references.citation: Am J Physiol. 1997 Jun;272(6 Pt 2):R2040-7
references.pmid: 9227626
references.citation: Life Sci. 1995;56(6):379-87
references.pmid: 7830499
references.citation: Peptides. 2006 Dec;27(12):3154-64
references.pmid: 17092606
references.citation: J Cardiovasc Pharmacol. 2011 Jul;58(1):25-31
references.pmid: 21436721
references.citation: Hypertension. 2002 Jan;39(1):93-8
references.pmid: 11799085
references.citation: Biochem Biophys Res Commun. 2005 Feb 18;327(3):713-9
references.pmid: 15649405
references.citation: Peptides. 2007 May;28(5):1095-103
references.pmid: 17346853
references.citation: FEBS Lett. 2004 Jan 2;556(1-3):53-8
references.pmid: 14706825
references.citation: Clin Exp Pharmacol Physiol. 2004 Dec;31 Suppl 2:S49-50
references.pmid: 15649289
references.citation: Circ Heart Fail. 2008 Jul;1(2):134-42
references.pmid: 19808282
references.citation: Br J Clin Pharmacol. 2001 Aug;52(2):165-8
references.pmid: 11488773
references.citation: Circulation. 1997 Sep 16;96(6):1983-90
references.pmid: 9323090
references.citation: Peptides. 1997;18(5):733-9
references.pmid: 9213369
references.citation: Regul Pept. 2003 Apr 15;112(1-3):51-60
references.pmid: 12667625
references.citation: Peptides. 2004 Oct;25(10):1643-56
references.pmid: 15476931